At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 314 enrolled
Drug / intervention
Esomeprazole 40 mg +3 moredrug
Likely dose
Esomeprazole 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
In Brief
A Phase 4 clinical trial evaluating Esomeprazole 40 mg, Physical Exam, and 2 other interventions for Gastroesophageal Reflux Disease. Completed, enrolled 314 participants across 10 sites in 4 countries.
Detailed Summary
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease
CountriesArgentina, Chile, Colombia, Venezuela
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedAug 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedAug 13, 2008
Enrollment StartNov 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.9 years ago
Interventions
Esomeprazole 40 mgdrug
Once a day
Physical Examprocedure
every visit
Quality of Life Questionnairesother
every visit
pregnancy test, if applicableprocedure
as needed